![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Introduction: Some gene expression regulation in cancers can be controlled by epigenetic change like methylation. PTEN promoter methylation and expression were evaluated in endometrial cancer. Methods: The study was run on 39 tumor tissues of endometrial cancer patients and 41 normal endometrial tissues. After total RNA extraction, cDNA synthesis was done by reverse transcription of the total (real-time PCR) using SYBER Green master mix. DNA extraction and bisulfite treatment were conducted and methylation was semiquantified by the methylation-sensitive high-resolution melting method. Finally, promoter methylation quantification of the total number of 25 tumors and 22 non-neoplastic tissues was done. Results:PTEN gene expression showed a significant decrease in endometrial cancer tissues. Promoter methylation was significantly lower in the non-neoplastic group (7.2; p < 0.001). In addition, PTEN promoter methylation was observed in 52.0% of tumor tissues compared with 13.6% in the non-neoplastic group (p = 0.06). There were no significant correlations between PTEN expression and methylation and clinicopathological features in endometrial cancer patients (p > 0.05). Conclusion:PTEN gene expression in endometrial cancer tissues decreased because of its promoter hypermethylation.
MM Amoli and M Asadi designed the study and analysed the data. SH Shahriari and S Aminimoghaddam wrote the manuscript. FK Khatami edited the manuscript. Z Nickhah Kalashami and MSH Farahani ran the molecular testing and BH Rashidi collected the samples. L Teimoori-Toolabi supervised the manuscript.
Acknowledgments
The authors would like to give their highest thanks to the participants of this study, including patients and their families. This study was funded by Vali-e Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran (30022-39-03-94).
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The study was approved by the Tehran University of Medical Sciences ethics committee (IR.TUMS.REC.1399.1787). Patients agreed to recruit for the study by signing written informed consent and all methods were performed in accordance with the relevant guidelines and regulations. All patients agreed to the study by signing written informed consent with an agreement to publish data anonymously.
Data sharing statement
All necessary data are included in the manuscript and no additional data are included. The methylation data is not mega data and does not require relevant accession numbers or the name of the database. Methylation data is not mega data and are not the same as next-generation sequencing data or array data so all data are included in the article and no additional data exist.